A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

被引：0
|
作者：
Li, Jianyong
Zhou, Keshu
Nian, Weiqi
Cui, Guohui
Wang, Jishi
Zhang, Xiaoping
Cen, Hong
Li, Fei
Yi, Shuhua
Feng, Ru
Xu, Chongyuan
Qian, Wenbin
Liu, Lihong
Li, Caixia
Zhao, Xielan
Chen, Zi
Qiao, Junxiao
Zhang, Hongli
Ahmad, Mohammad
Zhai, Yifan
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[5] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China
[6] Southeast Univ, Zhongda Hosp, Nanjing, Peoples R China
[7] Guangxi Med Univ, Dept Med Oncol, Affiliated Canc Hosp, Nanning, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[9] Chinese Acad Med Sci, Hematol Hosp, Beijing, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[11] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Hangzhou, Peoples R China
[12] Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Peoples R China
[13] Suzhou First Peoples Hosp, Suzhou, Peoples R China
[14] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China
[15] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[16] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Chen, Zi
    Huang, Bo
    Konopleva, Marina
    Brander, Danielle M.
    Rizzieri, David
    Lasica, Masa
    Tam, Constantine Si Lun
    Yannakou, Costas K.
    Prince, H. Miles
    Davids, Matthew Steven
    He, Zhicong
    Lu, Ming
    Ahmad, Mohammad
    Li, Mingyu
    Liang, Zhiyan
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)
    Sun, Mingyuan
    Qi, Junyuan
    Chen, Zi
    Zhang, Hongli
    Song, Yongping
    Shen, Aizong
    Liu, Huilan
    Huang, Jianying
    Zhou, Fuling
    Jin, Jie
    Lu, Ming
    Ahmad, Mohammad
    Men, Lichuang
    Cen, Wan
    Yang, Dajun
    Wang, Jianxiang
    Zhai, Yifan
    BLOOD, 2021, 138 : 3730 - +
  • [3] Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)
    Davids, Matthew S.
    Siddiqi, Tanya
    Chanan-Khan, Asher
    Skarbnik, Alan
    Winter, Allison M.
    Pagel, John M.
    Smith, Carrie
    Gabrail, Nashat
    Perekhrestenko, Tetiana
    Pylypenko, Halyna
    Kyselova, Olena
    Karpenko, Olena
    Popovska, Tetiana
    Kriachok, Iryna
    Usenko, Hanna
    Proidakov, Andrew
    Ivanov, Vladimir
    Lysa, Tamila
    Borisenkova, Elena
    Bakirov, Bulat
    Lukavetsky, Les
    Uspenskaya, Olga
    Konstantinova, Tatiana S.
    Samoylova, Olga S.
    Chen, Zi
    Huang, Bo
    Li, Mingyu
    Ahmad, Mohammad
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2021, 138
  • [4] Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naive, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
    Davids, Matthew S.
    Chanan-Khan, Asher
    Mudenda, Boyd
    Nogaieva, Larysa
    Kriachok, Iryna
    Usenko, Hanna
    Ivanov, Vladimir
    Kyselova, Olena
    Perekhrestenko, Tetiana
    Muzhychuk, Ivan
    Myasnikov, Alexander
    Maslyak, Zvenyslava
    Proidakov, Andrew
    Uspenskaya, Olga
    Borisenkova, Elena
    Marlton, Paula
    Siddiqi, Tanya
    Winter, Allison
    Lysa, Tamila
    Bakirov, Bulat
    Fu, Lei
    Chen, Zi
    Yu, Min
    Li, Mingyu
    Glass, Laura
    Ahmad, Mohammad
    Karpenko, Olena
    Osipov, Iurii
    De, Asit
    Paudyal, Ben
    Wang, Hengbang
    Winkler, Robert
    Gabrail, Nashat
    Ganju, Vinod
    Konstantinova, Tatiana S.
    Samoylova, Olga S.
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2022, 140 : 2326 - 2328
  • [5] Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms
    Wang, Huafeng
    Wei, Xudong
    Jiang, Qian
    He, Wenjun
    Li, Qiubai
    Liang, Yang
    Weng, Jianyu
    Chen, Suning
    Ma, Hongbing
    Chang, Chukang
    Xu, Yajing
    He, Qun
    Chen, Zi
    Liu, Lihui
    Men, Lichuang
    Cong, Danhua
    Zhang, Zhang
    Yang, Dajun
    Zhai, Yifan
    Jie, Jin
    BLOOD, 2023, 142
  • [6] First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
    Ailawadhi, Sikander
    Chen, Zi
    Huang, Bo
    Paulus, Aneel
    Collins, Mary
    Fu, Lei
    Li, Mingyu
    Ahmad, Mohammad
    Men, Lichuang
    Wang, Hengbang
    Davids, Matthew
    Liang, Eric
    Mekala, Divya
    He, Zhicong
    Lasica, Masa
    Yannakou, Costas
    Parrondo, Ricardo
    Glass, Laura
    Yang, Dajun
    Chanan-Khan, Asher
    Zhai, Yifan
    LEUKEMIA & LYMPHOMA, 2023, 64 : S76 - S77
  • [7] First-in-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients With Relapsed/Refractory CLL and Other Hematologic Malignancies
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 10 - 11
  • [8] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Humphrey, Kathryn
    Kim, Su Young
    Okubo, Sumiko
    Ogawa, Natsumi
    Nishimura, Yasuko
    Salem, Ahmed Hamed
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
  • [9] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Koji Izutsu
    Kazuhito Yamamoto
    Koji Kato
    Takayuki Ishikawa
    Noriko Fukuhara
    Yasuhito Terui
    Ilseung Choi
    Kathryn Humphrey
    Su Young Kim
    Sumiko Okubo
    Natsumi Ogawa
    Yasuko Nishimura
    Ahmed Hamed Salem
    Dai Maruyama
    International Journal of Hematology, 2021, 113 : 370 - 380
  • [10] Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed of refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Terui, Y.
    Ogura, M.
    Tobinai, K.
    Hatake, K.
    Suzuki, T.
    Muruyama, D.
    Miyazato, A.
    Katsura, K.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345